



FOR IMMEDIATE RELEASE

Christine McCarty
312 596 1617
cmccarty@ziegler.com

**Ziegler Advises Somnoware Healthcare Systems Inc.
On Acquisition by ResMed (NYSE: RMD)**

CHICAGO, IL – July 13, 2023 – Ziegler, a specialty investment bank, is pleased to announce its role as exclusive financial advisor to [Somnoware Healthcare Systems Inc.](#) (“Somnoware” or the “Company”) on its acquisition by [ResMed](#), a global sleep and respiratory care company.

Somnoware provides comprehensive sleep, respiratory and cardiopulmonary diagnostic, and care management software solutions. The Company’s cloud-based platform supports better data aggregation, more efficient provider workflows and diagnoses, and more effective patient monitoring for improved engagement, adherence, and patient outcomes. Founded in 2011, Somnoware is now used in over 1,500 testing centers across the U.S.

Somnoware’s diagnostic management platform is upstream of and complementary to ResMed’s offerings. This acquisition expands ResMed’s suite of sleep management software solutions and enables stronger connectivity across the patient journey from diagnosis through ongoing treatment and care management. The Somnoware platform will remain open, and device-agnostic so end users can keep interoperating with various testing solutions and place orders for treatment devices and accessories from any supplier.

“ResMed identified early on that Subath Kamalasan and his amazing team at Somnoware had developed an impactful platform that could help identify, engage, and keep patients compliant with their sleep and respiratory issues without disrupting any of the stakeholders’ existing daily workflows. These are themes Ziegler is consistently searching for in our prospective clients,” stated Grant Chamberlain, Senior Managing Director in Ziegler’s Healthcare Investment Banking Practice. Managing Directors, Adam Heller and Chris Swenson spearheaded the transaction alongside Grant Chamberlain.

“Somnoware was initially seeking to raise a growth capital round to support the Company’s numerous growth opportunities. Ziegler helped guide us through a process that resulted in significant interest including a wide range of potential strategic alternatives. Ziegler was an instrumental advisor to us as we evaluated the different proposals. Ultimately, the opportunity to partner with ResMed on a shared mission of guiding people toward better sleep and improved breathing was too compelling to pass up and we could not be happier with the outcome,” added Subath Kamalasan, CEO and Co-Founder of Somnoware.

King & Spalding provided legal counsel to Somnoware, and DLA Piper served as legal counsel to ResMed in connection with the transaction.

Ziegler’s Healthcare Investment Banking team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals, and senior living, Ziegler is one of the most active M&A firms offering differentiated sell-side, buy-side, recapitalization/restructuring, equity private placement, and strategic partnering services.

For more information about Ziegler, please visit us at www.ziegler.com.

About Ziegler:

Ziegler is a privately held investment bank, capital markets, and proprietary investments firm. Specializing in the healthcare, senior living and education sectors, as well as general municipal and structured finance, enables Ziegler to generate a positive impact on the clients and communities it serves. Headquartered in Chicago with regional and branch offices throughout the United States, Ziegler provides its clients with capital raising, strategic advisory services, equity and fixed income sales & trading and research. To learn more, visit www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.